Ken Griffin Gritstone Bio, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$0.45 - $0.71 $17,685 - $27,903	-39,300 Reduced 39.66%	59,800 $34,000
Q2 2024 Aug 14, 2024	SELL	$0.62 - $2.35 $101,804 - $385,870	-164,200 Reduced 62.36%	99,100 $61,000
Q1 2024 May 15, 2024	BUY	$1.96 - $2.9 $417,088 - $617,120	212,800 Added 421.39%	263,300 $676,000
Q4 2023 Feb 14, 2024	BUY	$1.28 - $2.85 $48,896 - $108,870	38,200 Added 310.57%	50,500 $103,000
Q3 2023 Nov 14, 2023	SELL	$1.19 - $2.26 $4,284 - $8,135	-3,600 Reduced 22.64%	12,300 $21,000
Q2 2023 Aug 14, 2023	SELL	$1.66 - $3.03 $46,812 - $85,446	-28,200 Reduced 63.95%	15,900 $31,000
Q1 2023 May 15, 2023	BUY	$2.13 - $3.74 $54,315 - $95,370	25,500 Added 137.1%	44,100 $122,000
Q4 2022 Feb 14, 2023	SELL	$2.17 - $3.92 $20,615 - $37,240	-9,500 Reduced 33.81%	18,600 $64,000
Q3 2022 Nov 14, 2022	SELL	$2.46 - $4.75 $99,876 - $192,850	-40,600 Reduced 59.1%	28,100 $72,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.